Varda Space Industries has unveiled a collaboration with United Therapeutics, a biotech firm recognized for its work on treatments for rare respiratory conditions and organ transplants. This partnership aims to utilize Varda's innovative in-orbit technology to test small molecule drugs. The project could pave the way for advancements in pharmaceuticals developed in microgravity, leading to significant changes in the drug manufacturing sector.
Over the past few years, Varda has conducted experiments in space, focusing on the automated manipulation of small molecules essential for numerous medications, including antibiotics and corticosteroids. According to Michael Reilly, Varda's chief strategy officer, the process of creating novel crystal seeds in orbit is surprisingly cost-effective.
By leveraging the unique conditions of space, Varda intends to produce larger and more uniform crystals, offering potential improvements in drug solubility and dosage efficiency. Anne Wilson, a chemist, has noted that these advancements could reduce treatment costs and enhance drug delivery methods, including the transition from intravenous to subcutaneous administration for therapies like monoclonal antibodies.